U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H4N2O2
Molecular Weight 112.0868
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of URACIL

SMILES

O=C1NC=CC(=O)N1

InChI

InChIKey=ISAKRJDGNUQOIC-UHFFFAOYSA-N
InChI=1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)

HIDE SMILES / InChI
Molecular Formula C4H4N2O2
Molecular Weight 112.0868
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.drugbank.ca/drugs/DB03419 | https://www.drugs.com/international/uracil.html | https://www.ncbi.nlm.nih.gov/pubmed/28347333 | https://www.ncbi.nlm.nih.gov/pubmed/4053028

Uracil is a common and naturally occurring pyrimidine derivative, one of the four nucleobases in the nucleic acid of RNA In RNA, uracil binds to adenine via two hydrogen bonds. In DNA, the uracil nucleobase is replaced by it’s methylated form -- thymine. Originally discovered in 1900 by Alberto Ascoli, it was isolated by hydrolysis of yeast nuclein;[4] it was also found in bovine thymus and spleen, herring sperm, and wheat germ. It is a planar, unsaturated compound that has the ability to absorb light. Uracil readily undergoes regular reactions including oxidation, nitration, and alkylation. While in the presence of phenol (PhOH) and sodium hypochlorite (NaOCl), uracil can be visualized in ultraviolet light. Uracil also has the capability to react with elemental halogens because of the presence of more than one strongly electron donating group. Uracil readily undergoes addition to ribose sugars and phosphates to partake in synthesis and further reactions in the body. Uracil becomes uridine, uridine monophosphate (UMP), uridine diphosphate (UDP), uridine triphosphate (UTP), and uridine diphosphate glucose (UDP-glucose). Each one of these molecules is synthesized in the body and has specific functions. Uracil's use in the body is to help carry out the synthesis of many enzymes necessary for cell function through bonding with riboses and phosphates. Uracil serves as allosteric regulator and coenzyme for reactions in the human body and in plants. Uracil can be used for drug delivery and as a pharmaceutical. When elemental fluorine is reacted with uracil, 5-fluorouracil is produced. 5-Fluorouracil is an anticancer drug (antimetabolite) used to masquerade as uracil during the nucleic acid replication process. In combination with Tegafur, uracil used as a chemotherapy drug (called UFT or UFUR) used in the treatment of cancer, primarily bowel cancer. UFT is an anticancer medication composed of a fixed molar ratio (1:4) of tegafur and uracil to be administered with calcium folinate.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Substrate
661
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Uftoral

Approved Use

INDICATIONS. UFT is indicated for the first-line treatment of metastatic colorectal cancer with calcium folinate
Primary
Phase II
1132
Uftoral

Approved Use

INDICATIONS. UFT is indicated for the first-line treatment of metastatic colorectal cancer with calcium folinate
Primary
Phase II
1132
Uftoral

Approved Use

INDICATIONS. UFT is indicated for the first-line treatment of metastatic colorectal cancer with calcium folinate
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
20.3 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8612313/
350 mg/m² 1 times / day steady-state, oral
dose: 350 mg/m²
route of administration: Oral
experiment type: STEADY-STATE
co-administered: TEGAFUR
TEGAFUR
 URACIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
20.1 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/8612313/
350 mg/m² 1 times / day steady-state, oral
dose: 350 mg/m²
route of administration: Oral
experiment type: STEADY-STATE
co-administered: TEGAFUR
TEGAFUR
 URACIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg/m2 single, oral
Highest studied dose
Dose: 1000 mg/m2
Route: oral
Route: single
Dose: 1000 mg/m2
Sources:
https://pubmed.ncbi.nlm.nih.gov/21590448
healthy, 38 ± 9 years
n = 4
Health Status: healthy
Age Group: 38 ± 9 years
Sex: M+F
Population Size: 4
Sources:
https://pubmed.ncbi.nlm.nih.gov/21590448
Sources:
https://pubmed.ncbi.nlm.nih.gov/21590448
248.4 mg/m2 1 times / day steady, oral
RP2D
Dose: 248.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248.4 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(111.6 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 54 years
n = 6
Health Status: unhealthy
Condition: carcinoma
Age Group: 54 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Other AEs: Fatigue, Nausea...
Other AEs:
Fatigue (grade 1-2, 3 patients)
Nausea (grade 1-2, 2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
552 mg/m2 1 times / day steady, oral
RP2D
Dose: 552 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 552 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(248 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 59 years
n = 8
Health Status: unhealthy
Condition: carcinoma
Age Group: 59 years
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Other AEs: Granulocytopenia, Nausea...
Other AEs:
Granulocytopenia (grade 4, 1 patient)
Nausea (grade 3, 1 patient)
Thrombocytopenia (grade 3, 1 patient)
Vomiting (grade 1-2, 5 patients)
Fatigue (grade 1-2, 4 patients)
Diarrhoea (grade 1-2, 4 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
310.5 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 310.5 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 310.5 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(139.5 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
unhealthy
n = 6
Health Status: unhealthy
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
621 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 621 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 621 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(279 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
unhealthy
n = 5
Health Status: unhealthy
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
DLT: Granulocytopenia...
Dose limiting toxicities:
Granulocytopenia (grade 4, 4 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
276 mg/m2 1 times / day steady, oral
Dose: 276 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 276 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(124 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
unhealthy
n = 8
Health Status: unhealthy
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
DLT: Diarrhea...
Dose limiting toxicities:
Diarrhea (grade 3-4, 3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
AEs

AEs

AESignificanceDosePopulation
Nausea grade 1-2, 2 patients
248.4 mg/m2 1 times / day steady, oral
RP2D
Dose: 248.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248.4 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(111.6 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 54 years
n = 6
Health Status: unhealthy
Condition: carcinoma
Age Group: 54 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Fatigue grade 1-2, 3 patients
248.4 mg/m2 1 times / day steady, oral
RP2D
Dose: 248.4 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 248.4 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(111.6 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 54 years
n = 6
Health Status: unhealthy
Condition: carcinoma
Age Group: 54 years
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Diarrhoea grade 1-2, 4 patients
552 mg/m2 1 times / day steady, oral
RP2D
Dose: 552 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 552 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(248 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 59 years
n = 8
Health Status: unhealthy
Condition: carcinoma
Age Group: 59 years
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Fatigue grade 1-2, 4 patients
552 mg/m2 1 times / day steady, oral
RP2D
Dose: 552 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 552 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(248 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 59 years
n = 8
Health Status: unhealthy
Condition: carcinoma
Age Group: 59 years
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Vomiting grade 1-2, 5 patients
552 mg/m2 1 times / day steady, oral
RP2D
Dose: 552 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 552 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(248 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 59 years
n = 8
Health Status: unhealthy
Condition: carcinoma
Age Group: 59 years
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Nausea grade 3, 1 patient
552 mg/m2 1 times / day steady, oral
RP2D
Dose: 552 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 552 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(248 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 59 years
n = 8
Health Status: unhealthy
Condition: carcinoma
Age Group: 59 years
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Thrombocytopenia grade 3, 1 patient
552 mg/m2 1 times / day steady, oral
RP2D
Dose: 552 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 552 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(248 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 59 years
n = 8
Health Status: unhealthy
Condition: carcinoma
Age Group: 59 years
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Granulocytopenia grade 4, 1 patient
552 mg/m2 1 times / day steady, oral
RP2D
Dose: 552 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 552 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(248 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
unhealthy, 59 years
n = 8
Health Status: unhealthy
Condition: carcinoma
Age Group: 59 years
Sex: M+F
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
https://pubmed.ncbi.nlm.nih.gov/8949982
Diarrhea grade 3-4, 3 patients
DLT
310.5 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 310.5 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 310.5 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(139.5 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
unhealthy
n = 6
Health Status: unhealthy
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
Granulocytopenia grade 4, 4 patients
DLT
621 mg/m2 1 times / day steady, oral
Highest studied dose
Dose: 621 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 621 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(279 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
unhealthy
n = 5
Health Status: unhealthy
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
Diarrhea grade 3-4, 3 patients
DLT
276 mg/m2 1 times / day steady, oral
Dose: 276 mg/m2, 1 times / day
Route: oral
Route: steady
Dose: 276 mg/m2, 1 times / day
Co-administed with::
TEGAFUR(124 mg/m2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
unhealthy
n = 8
Health Status: unhealthy
Population Size: 8
Sources:
https://pubmed.ncbi.nlm.nih.gov/9348565
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1461
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1650
 no
PubMed

PubMed

TitleDatePubMed
Applications of microarray technology in breast cancer research.
2001
The oral fluorinated pyrimidines.
2001
NRG1 is required for glucose repression of the SUC2 and GAL genes of Saccharomyces cerevisiae.
2001
Fungal virulence studies come of age.
2001
Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer.
2001
Acid-catalyzed photoreaction of 6-chloro-1,3-dimethyluracil and mesitylene: formation of photocycloadducts and their characterization.
2001 Apr
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
2001 Apr
Tuber physiology and properties of starch from tubers of transgenic potato plants with altered plastidic adenylate transporter activity.
2001 Apr
[(35)S]GTPgammaS autoradiography reveals a wide distribution of G(i/o)-linked ADP receptors in the nervous system: close similarities with the platelet P2Y(ADP) receptor.
2001 Apr
Photocatalytic degradation of the cyanotoxin cylindrospermopsin, using titanium dioxide and UV irradiation.
2001 Apr
Low-energy (5-40 eV) electron-stimulated desorption of anions from physisorbed DNA bases.
2001 Apr
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
2001 Apr 1
Analysis of gene induction and arrest site transcription in yeast with mutations in the transcription elongation machinery.
2001 Apr 13
DNA repair and aging in mouse liver: 8-oxodG glycosylase activity increase in mitochondrial but not in nuclear extracts.
2001 Apr 15
The role of folic acid and Vitamin B12 in genomic stability of human cells.
2001 Apr 18
DNA damage from micronutrient deficiencies is likely to be a major cause of cancer.
2001 Apr 18
A possible role of Ku in mediating sequential repair of closely opposed lesions.
2001 Apr 20
Characterization of the full length uracil-DNA glycosylase in the extreme thermophile Thermotoga maritima.
2001 Apr 4
Why Ppr1p is a weak activator of transcription.
2001 Apr 6
N(1)-C(5')-linked dimer hydrates of 5-substituted uracils produced by anodic oxidation in aqueous solution.
2001 Apr 6
First report of the cyanobacterial toxin cylindrospermopsin in New Zealand.
2001 Aug
Caffeine metabolism before and after liver transplantation.
2001 Feb
Confounded cytosine! Tinkering and the evolution of DNA.
2001 Feb
Quantum-chemical analysis of C-H...O and C-H...N interactions in RNA base pairs--H-bond versus anti-H-bond pattern.
2001 Feb
Uracil moiety is required for toxicity of the cyanobacterial hepatotoxin cylindrospermopsin.
2001 Feb 23
5-Formyluracil and its nucleoside derivatives confer toxicity and mutagenicity to mammalian cells by interfering with normal RNA and DNA metabolism.
2001 Feb 3
The effect of UV irradiation on uracil thin layer measured by optical waveguide lightmode spectroscopy.
2001 Jan
Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer.
2001 Jan
Novel synthesis of seco type of acyclo C-nucleosides of 1,2,4-triazole and 1,2,4-triazol.
2001 Jan-Feb
Preparation of oligodeoxynucleotides containing 5-(N-methylpiperazinyl) and 5-benzyloxymethyl uracils.
2001 Jan-Feb
[New drugs for colorectal cancer: UFT].
2001 Jan-Feb
Methylenetetrahydrofolate reductase polymorphism is associated with folate pool in gastrointestinal cancer tissue.
2001 Jan-Feb
Postsurgical sequential methotrexate/5-FU and leucovorin on outpatient basis for advanced colorectal carcinoma.
2001 Jan-Feb
Isolation and characterization of a U-specific 3'-5'-exonuclease from mitochondria of Leishmania tarentolae.
2001 Jun 15
Future directions in adjuvant therapy for stage III colon carcinoma.
2001 Mar
Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
2001 Mar
The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.
2001 Mar
[A case of advanced gastric cancer complicated with liver metastases responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin, with UFT and low-dose cisplatin for maintenance on an outpatient basis].
2001 Mar
P2Y receptor-mediated inhibition of voltage-activated Ca(2+) currents in PC12 cells.
2001 Mar
HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3' untranslated regions of cytokine and angiogenic factor mRNAs.
2001 Mar 1
[Long-term survival of hormone-refractory prostate cancer: a case report].
2001 Mar 1
5'-Deoxyribose phosphate lyase activity of human DNA polymerase iota in vitro.
2001 Mar 16
Identification and quantification of base and nucleoside markers in extracts of Ganoderma lucidum, Ganoderma japonicum and Ganoderma capsules by micellar electrokinetic chromatography.
2001 Mar 9
Structural determinants of adenophostin A activity at inositol trisphosphate receptors.
2001 May
Role of MED1 (MBD4) Gene in DNA repair and human cancer.
2001 May
Validity of an ELISA for N-acetyltransferase-2 (NAT2) phenotyping.
2001 May 1
Functionally different AU- and G-rich cis-elements confer developmentally regulated mRNA stability in Trypanosoma cruzi by interaction with specific RNA-binding proteins.
2001 May 11
Oxidation of thymine to 5-formyluracil in DNA promotes misincorporation of dGMP and subsequent elongation of a mismatched primer terminus by DNA polymerase.
2001 May 11
Chimeras between single-stranded DNA-binding proteins from Escherichia coli and Mycobacterium tuberculosis reveal that their C-terminal domains interact with uracil DNA glycosylases.
2001 May 18
The role of leucine 191 of Escherichia coli uracil DNA glycosylase in the formation of a highly stable complex with the substrate mimic, ugi, and in uracil excision from the synthetic substrates.
2001 May 18
Patents

Patents

04447605
2
05698685
3
05705616
1
06077812
2
06342504
1
08227594
1
20010006787
5

Sample Use Guides

In Vivo Use Guide
UFT (tegafur- uracil) is an anticancer medication composed of a fixed molar ratio (1:4) of tegafur and uracil to be administered with calcium folinate. The usual dose is 300 mg/m2/day tegafur-uracil 90 mg/day calcium folinate (30 mg/dose) administered in three divided doses (every 8 hours) orally one hour before or one hour after meals for 28 consecutive days.
Route of Administration: Oral
In Vitro Use Guide
A cultured line of human lymphoid cells (8866) was grown in suspension in modified Eagle's medium plus 10% (vol/vol) fetal calf serum. All experiments were carried out with 20-S0 ml of cells in logarithmic phase of growth (6-9 X 105 cells per ml). Cells were incubated with methotrexate (10 ,gM) plus hypoxanthine (25 jM) (serine and glycine were already present in the medium) for 4 hr, after which [5-3H]dUrd (15-20 Ci/mmol, 1 Ci = 3.7 X 1010 becquerels; Moravek, City of Industry, CA) was added at levels specified and incubation was continued for an additional 2 hr. Cultures not treated with methotrexate were labeled for 30 rmin (in the presence of hypoxanthine alone). Ura, when present, was added at 10 mM 10 min before [3H]dUrd.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:06:24 GMT 2023
Edited
by admin
on Fri Dec 15 15:06:24 GMT 2023
Record UNII
56HH86ZVCT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
URACIL
INCI   JAN   MART.   MI   USAN   USP-RS   WHO-DD  
USAN   INCI  
Official Name English
LAMIVUDINE IMPURITY E [USP IMPURITY]
Common Name English
PYRIMIDINE-2,4(1H,3H)-DIONE
Systematic Name English
NSC-3970
Code English
2,4(1H,3H)-PYRIMIDINEDIONE
Systematic Name English
URACIL [USAN]
Common Name English
Uracil [WHO-DD]
Common Name English
SQ-7726
Code English
URACIL [MART.]
Common Name English
SQ-8493
Code English
PYROD
Common Name English
URACIL [JAN]
Common Name English
SQ-6201
Code English
URACIL [MI]
Common Name English
BMS-205603-01
Code English
LAMIVUDINE IMPURITY F [EP IMPURITY]
Common Name English
FLUOROURACIL IMPURITY C [EP IMPURITY]
Common Name English
URACIL [USP-RS]
Common Name English
FLUOROURACIL SPECIFIED COMPOUND C [USP IMPURITY]
Common Name English
HYBAR X
Common Name English
URACIL [INCI]
Common Name English
Classification Tree Code System Code
LOINC 75152-9
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
LOINC 30485-7
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
NCI_THESAURUS C789
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
LOINC 13819-8
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
LOINC 75128-9
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
LOINC 25140-5
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C917
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
MERCK INDEX
m11305
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY Merck Index
PUBCHEM
1174
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
MESH
D014498
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
ChEMBL
CHEMBL566
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID4021424
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
RS_ITEM_NUM
1705753
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
CAS
66-22-8
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
RXCUI
10995
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY RxNorm
CHEBI
17568
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
DRUG BANK
DB03419
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
EVMPD
SUB20762
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
WIKIPEDIA
URACIL
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
USAN
KK-14
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-621-9
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
NSC
3970
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
FDA UNII
56HH86ZVCT
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
SMS_ID
100000086536
Created by admin on Fri Dec 15 15:06:24 GMT 2023 , Edited by admin on Fri Dec 15 15:06:24 GMT 2023
PRIMARY
Related Record Type Details
Structure of LAMIVUDINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYTARABINE
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FLUOROURACIL
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYTARABINE
PARENT -> IMPURITY
Related Record Type Details
Structure of URACIL
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966